Work for Supernus Pharmaceuticals, Inc.?

Claim Your Profile

Supernus Pharmaceuticals, Inc. Logo Image

Supernus Pharmaceuticals, Inc.

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

2018 Annual Report and Form 10K

Supernus Pharmaceuticals, Inc.

Annual
Report

Supernus Pharmaceuticals, Inc. has reached its limit for free report views.

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

Archived Annual Reports

  • Supernus Pharmaceuticals, Inc.
  • Supernus Pharmaceuticals, Inc.

About Supernus Pharmaceuticals, Inc.

201-500 Employees
Based in Rockville, Maryland

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients, SPN-812 for the treatment of ADHD and SPN-604 for the treatment of bipolar disorder.

Ticker:
SUPN
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Drug Manufacturers - Other (See More Drug Manufacturers - Other Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol